ValiRx: Bioscience Innovation

19:00 EDT 24 Jun 2008 | PharmaTelevision

In this interview, filmed during BioEurope 2008 in Madrid, Fintan Walton speaks with Satu Vainikka, CEO of ValiRx, an AIM listed biopharmaceutical company based in the UK. Focusing on epigenetics, ValiRx is developing novel technologies and products in oncology therapeutics and diagnostics. They act as a "mother" company to the two companies they have developed to concentrate on these separate goals: Cronos, focusing on cancer therapeutics; and ValiBIO, which focuses on cancer diagnostics. Within these companies, ValiRx has created unique partnerships with academia that allows them to utilise those distribution channels that have already been created and to provide the institution with revenue from future royalties. As subsequent complementary opportunities are identified by ValiRx, it is feasible that their portfolio of companies will continue to grow as they capitalise on their experience in transferring technologies and products into the commercial arena.

Original Article: ValiRx: Bioscience Innovation


More From BioPortfolio on "ValiRx: Bioscience Innovation"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...